Literature DB >> 8994419

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.

B Lamarche1, A Tchernof, S Moorjani, B Cantin, G R Dagenais, P J Lupien, J P Després.   

Abstract

BACKGROUND: Case-control studies have reported that patients with ischemic heart disease (IHD) have a higher proportion of small, dense LDL particles than do healthy control subjects. The extent to which the risk attributed to small LDL particles may be independent of concomitant variations in plasma lipoprotein-lipid concentrations remains to be clearly determined, however, particularly through prospective studies. METHODS AND
RESULTS: Baseline characteristics were obtained in 2103 men initially free of IHD, among whom 114 developed IHD during a 5-year follow-up period. These 114 case patients were matched with healthy control subjects for age, body mass index, smoking habits, and alcohol intake. LDL peak particle diameter (PPD) was measured a posteriori in 103 case-control pairs by nondenaturing gradient gel electrophoresis of whole plasma. Conditional logistic regression analysis of the case-control status revealed that men in the first tertile of the control LDL-PPD distribution (LDL-PPD < or = 25.64 nm) had a 3.6-fold increase in the risk of IHD (95% CI, 1.5 to 8.8) compared with those in the third tertile (LDL-PPD > 26.05 nm). Statistical adjustment for concomitant variations in LDL cholesterol, triglycerides, HDL cholesterol, and apolipoprotein B concentrations had virtually no impact on the relationship between small LDL particles and the risk of IHD.
CONCLUSIONS: These results represent the first prospective evidence suggesting that the presence of small, dense LDL particles may be associated with an increased risk of subsequently developing IHD in men. Results also suggest that the risk attributed to small LDL particles may be partly independent of the concomitant variation in plasma lipoprotein-lipid concentrations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8994419     DOI: 10.1161/01.cir.95.1.69

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  181 in total

1.  Small, dense, low-density lipoprotein and atherosclerosis.

Authors:  H R Superko
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  LDL particle size: an important drug target?

Authors:  I Rajman; P I Eacho; P J Chowienczyk; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

3.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

Review 4.  The medical risks of obesity.

Authors:  F Xavier Pi-Sunyer
Journal:  Obes Surg       Date:  2002-04       Impact factor: 4.129

Review 5.  Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease.

Authors:  H N Ginsberg
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

6.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

7.  Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance.

Authors:  Brian A Irving; K Sreekumaran Nair; Manivannan Srinivasan
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

8.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 9.  Lipid abnormalities in the metabolic syndrome.

Authors:  Eliot A Brinton
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 10.  Treatment of lipids and type 2 diabetes.

Authors:  Kathie L Hermayer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.